Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2/3 1Phase 2 1

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

Gastrointestinal 5Endocrine 5NET 4Genitourinary 1

Conditions

Neuroendocrine Tumors 4Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

lutetium Lu 177 dotatate 41Everolimus 38Magnetic Resonance Spectroscopy 18Temozolomide 17lanreotide 16gallium Ga 68 dotatate 15Octreotide 14pembrolizumab 13Nivolumab 13Capecitabine 12cabozantinib 11177Lu-octreotide, DOTA(0)-Tyr(3)- 11surufatinib 9pasireotide 9Sunitinib 9Specimen Handling 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9Lutetium-177 8Carboplatin 8amino-acid, glucose, and electrolyte solution 6Ipilimumab 6Ga(III)-DOTATOC 6Fluorodeoxyglucose F18 6Etoposide 6Cisplatin 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5copper dotatate CU-64 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Somatostatin × NET × Clear all
NCT06855095 2025-03-03

ATSA

The Netherlands Cancer Institute

Phase 2/3 Recruiting
39 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05701241 2024-06-14

SAUNA

University Hospital, Antwerp

Phase 4 Recruiting
270 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT04129255 2020-09-10

CSMS99

National Cancer Institute, Naples

Phase 2 Completed
34 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01755182 2016-05-06

LOTUS

National Cancer Institute, Naples

Phase 3 Terminated
1 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡